Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Study Summary

The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.

Conditions

Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

Interventions / Drugs

Maralixibat Placebo

View on ClinicalTrials.gov ↗

Sponsor

MIRM

Mirum Pharmaceuticals

Liver Disease

D37/100

Study Details

Enrollment90 participants

Primary Completion—

Lead SponsorMirum Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:21:18.704647+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.